OGN trades 16.4% above Wall Street's consensus target of $11.33.
Last 12 months price action with 12-month analyst target path
The base valuation assumes OGN achieves its forward estimates and maintains a stable P/E multiple of 4.0x. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 7, 2026, Organon & Co. (OGN) has a Wall Street consensus price target of $11.33, based on estimates from 9 covering analysts. With the stock currently trading at $13.56, this represents a potential downside of -16.4%. The company has a market capitalization of $3.56B.
Analyst price targets range from a low of $8.00 to a high of $14.00, representing a 53% spread in expectations. The median target of $12.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 2 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 3 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, OGN trades at a trailing P/E of 18.8x and forward P/E of 4.0x. Analysts expect EPS to grow +262.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $40.32, with bear and bull scenarios of $25.40 and $53.13 respectively. Model confidence stands at 38/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
PFEPfizer Inc. | $134.9B | $23.72 | $26.75 | +12.8% | Hold | 8.0x | 39 |
VTRSViatris Inc. | $19.6B | $16.80 | $17.40 | +3.6% | Hold | 6.8x | 13 |
ABBVAbbVie Inc. | $450.1B | $254.76 | $258.00 | +1.3% | Buy | 17.9x | 41 |
HLNHaleon plc | $43.3B | $9.72 | $10.20 | +4.9% | Buy | 23.4x | 4 |
TEVATeva Pharmaceutical Industries Limited | $38.9B | $33.44 | $40.00 | +19.6% | Buy | 15.9x | 46 |
PRGOPerrigo Company plc | $1.5B | $11.09 | $36.20 | +226.4% | Hold | 5.2x | 36 |
EVAXEvaxion Biotech A/S | $21M | $3.38 | — | — | — | — | — |
ANIPANI Pharmaceuticals, Inc. | $1.9B | $85.05 | $124.00 | +45.8% | Buy | 9.0x | 10 |
MCKMcKesson Corporation | $94.3B | $784.23 | $994.86 | +26.9% | Buy | 17.7x | 31 |
CAHCardinal Health, Inc. | $55.9B | $237.52 | $253.38 | +6.7% | Buy | 22.1x | 33 |
Quick answers to the most common questions about buying OGN stock.
OGN's consensus price target is $11.33, -16.4% below the current price of $13.56. The 9 analysts tracking OGN see downside risk at present valuations.
OGN has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is leaning bearish, with 3 Sell/Strong Sell ratings. The consensus 12-month price target of $11.33 implies -16.4% downside from current levels.
With a forward P/E of 4.0018x, OGN trades at a relatively low valuation. The consensus target of $11.33 implies -16.4% move, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $14 for OGN, while the most conservative target is $8. The consensus of $11.33 represents the median expectation. Our quantitative valuation model projects a bull case target of $53 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
OGN is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 4 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month OGN stock forecast based on 9 Wall Street analysts shows a consensus price target of $11.33, with estimates ranging from $8 (bear case) to $14 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $40, with bear/bull scenarios of $25/$53.
Our quantitative valuation model calculates OGN's fair value at $40 (base case), with a bear case of $25 and bull case of $53. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 38/100.
OGN trades at a forward P/E ratio of 4.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 18.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on OGN, with 3 Sell ratings and a price target of $11.33 (-16.4% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
OGN analyst price targets range from $8 to $14, a 53% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $11.33 consensus represents the middle ground. Our model's $25-$53 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.